Novo Nordisk reports significant weight loss in new drug study
The report offers no dosing or endpoint detail beyond the company's characterization of the weight-loss result.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 9 05:29 ETSource: BusinessWorld Online
The wire
- 01BusinessWorld reports a Novo Nordisk drug study showed significant weight loss results, without published figures for dose, duration or sample size.
- 02Prescribers and operators tracking the incretin pipeline will want the underlying data before changing how they counsel patients on options.
- 03Full results, the specific compound and any peer-reviewed or conference presentation remain unreported in this account.
From the source
Read at bworldonline.comnovo nordisk drug study shows significant weight loss results
